Deferiprone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Deferiprone: From Transfusional Iron Overload to Hepatic Porphyria
One-Sentence Summary
Deferiprone is an oral iron chelator used internationally to treat transfusion-dependent iron overload, particularly in patients with thalassaemia major when deferoxamine is inadequate or poorly tolerated. The TxGNN model predicts it may be effective for Hepatic Porphyria, with 0 clinical trials and 2 publications currently supporting this direction — both at a preclinical or animal model level. The overall evidence base remains early-stage, making this a research hypothesis rather than a clinically actionable repurposing candidate at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Transfusion-dependent iron overload (thalassaemia major) |
| Predicted New Indication | Hepatic Porphyria |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L4 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Deferiprone (3-hydroxy-1,2-dimethylpyridin-4(1H)-one) is a small-molecule oral iron chelator. Although detailed mechanism of action data is not available in this evidence pack, deferiprone is well recognised as an agent that reduces the labile iron pool within cells, thereby mitigating iron-mediated oxidative stress. Its low molecular weight (~139 Da) allows intracellular penetration — including entry into cardiomyocytes — an advantage over the larger parenteral chelator deferoxamine.
In hepatic porphyria — particularly porphyria cutanea tarda (PCT) — excess hepatic iron is a central pathogenic driver. Elevated hepatic iron upregulates δ-aminolevulinic acid synthase 1 (ALAS1), leading to the accumulation of phototoxic porphyrins in the liver. Reducing hepatic iron is already an established therapeutic strategy: therapeutic phlebotomy is the standard of care for PCT, validating the iron-depletion rationale. An oral iron chelator such as deferiprone could theoretically serve as an alternative for patients with anaemia who cannot tolerate venesection.
The biological rationale extends to congenital erythropoietic porphyria (CEP), where iron overload secondary to chronic haemolysis amplifies erythroid porphyrin accumulation and worsens photosensitivity. Preclinical evidence (see Literature Evidence below) suggests that iron chelation can rescue both haemolytic anaemia and skin photosensitivity in murine CEP models, lending translational support to the TxGNN prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32678895 | 2020 | Preclinical/Translational Study | Blood | Iron chelation rescued haemolytic anaemia and skin photosensitivity in a murine model of congenital erythropoietic porphyria (CEP), providing proof-of-concept that iron depletion can reduce porphyrin-driven pathology |
| 17854053 | 2007 | Animal Model Study | Hepatology | Deferiprone (L1) and iron-deficient diet comparably reduced hepatic uroporphyrin accumulation in Hfe(−/−) mice modelling porphyria cutanea tarda, directly supporting the oral iron chelation hypothesis in hepatic porphyria |
Australia Market Information
Deferiprone is not currently registered with the TGA and has no ARTG entries. It is not commercially available in Australia through standard regulatory channels. Access, if clinically indicated, would require the TGA Special Access Scheme (SAS) or Authorised Prescriber pathway.
Safety Considerations
No TGA-approved Product Information (PI) is available for deferiprone in Australia. There are no ARTG-registered safety data on record. Please refer to international regulatory documents — such as the EMA-approved Ferriprox Summary of Product Characteristics (SmPC) or the FDA-approved prescribing information — for comprehensive safety and prescribing guidance.
Key safety concerns known from published literature and international labelling include:
- Agranulocytosis / Neutropenia: The most serious known adverse effect. Agranulocytosis (ANC < 0.5 × 10⁹/L) has been reported and can be fatal. Weekly full blood count (FBC) with differential is mandatory during treatment; deferiprone must be discontinued immediately if neutropenia or agranulocytosis develops.
- Musculoskeletal effects: Arthropathy has been reported, particularly at higher doses.
- Gastrointestinal effects: Nausea, vomiting, and abdominal pain are among the most common adverse effects, particularly at treatment initiation.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic hypothesis is biologically plausible — hepatic iron drives porphyrin accumulation in PCT, and iron chelation is mechanistically analogous to the established phlebotomy approach — but the evidence base is limited to two preclinical/animal studies with no clinical trial data. Deferiprone is also not registered in Australia, precluding routine clinical use.
To proceed, the following is needed:
- Identify or initiate a Phase 1/2 pilot clinical trial evaluating deferiprone in hepatic porphyria (particularly PCT or CEP), focusing on hepatic iron reduction and porphyrin levels as primary endpoints
- Obtain complete MOA and safety data from DrugBank (DB08826) to enable a thorough mechanistic and risk–benefit assessment
- Review the EMA/FDA-approved Ferriprox labelling for full safety profile, drug interactions, and contraindications before any clinical application
- Assess the TGA Special Access Scheme (SAS Category B) or Authorised Prescriber pathway if off-label use in a specific patient is being considered
- Consult with a haematologist or metabolic disease specialist experienced in porphyria management before progressing to any clinical application
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.